NBIO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 bal. 2024 @ 18:03):

Stats
Dzisiejszy wolumen	1 700.00
Średni wolumen	63 766.00
Kapitalizacja rynkowa	16.96M
EPS	$0 ( 2024-02-14 )
Następna data zysków	( $0 ) 2024-06-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.99
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-31	Holden Lowell Thomas	Buy	112 500	Common Stock
2024-03-31	Carrick Sean	Buy	225 000	Common Stock
2024-03-31	Karas Douglas John	Buy	27 100	Common Stock
2023-12-29	Carrick Sean	Buy	239 300	Common Stock
2023-12-29	Holden Lowell Thomas	Buy	119 650	Common Stock

INSIDER POWER
58.65
Last 100 transactions
Buy: 40 920 261 \| Sell: 7 165 000

Nascent Biotech, Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nascent Biotech, Inc. Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-0.0236

FY	2023
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-0.0236

FY	2022
Przychody:	$1.00M
Zysk brutto:	$1.00M (100.00 %)
EPS:	$-0.00140

FY	2021
Przychody:	$750 000
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.0100

Financial Reports:

No articles found.

Nascent Biotech, Inc.

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.